Safelife Pharma Speciality Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 16-11-2024
- Paid Up Capital ₹ 5.00 M
as on 16-11-2024
- Company Age 8 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.55 Cr
as on 16-11-2024
- Revenue -17.68%
(FY 2023)
- Profit 7.38%
(FY 2023)
- Ebitda 23.65%
(FY 2023)
- Net Worth 158.71%
(FY 2023)
- Total Assets -3.40%
(FY 2023)
About Safelife Pharma Speciality
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹3.55 Cr.
Girish Mishra, Sandeep Mishra, and Shubha Mishra serve as directors at the Company.
- CIN/LLPIN
U74999MH2016PTC281825
- Company No.
281825
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 May 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Safelife Pharma Speciality Private Limited offer?
Safelife Pharma Speciality Private Limited offers a wide range of products and services, including Medical Consultants & Clinics, Pharmaceutical Chemists.
Who are the key members and board of directors at Safelife Pharma Speciality?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Girish Mishra  | Director | 03-Mar-2018 | Current |
| Sandeep Mishra | Director | 03-Mar-2018 | Current |
| Shubha Mishra | Director | 03-Mar-2018 | Current |
Financial Performance of Safelife Pharma Speciality.
Safelife Pharma Speciality Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 17.68% decrease. The company also saw a slight improvement in profitability, with a 7.38% increase in profit. The company's net worth Soared by an impressive increase of 158.71%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Safelife Pharma Speciality?
In 2023, Safelife Pharma Speciality had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Association Of Advanced Learners In MedicineActive 6 years 7 monthsGirish Mishra is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 09 May 2022 | ₹0.60 M | Open |
Others Creation Date: 01 Sep 2020 | ₹3.20 M | Open |
Others Creation Date: 17 Aug 2020 | ₹1.70 M | Open |
How Many Employees Work at Safelife Pharma Speciality?
Unlock and access historical data on people associated with Safelife Pharma Speciality, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Safelife Pharma Speciality, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Safelife Pharma Speciality's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
